Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
Multiple sclerosis (MS) is the most common disabling neurological disease of young adults. More than 2.3 million people are affected by MS worldwide. Symptoms can vary widely, depending on the localization and amount of the damage induced by combined inflammatory, demyelinating, and neurodegenerative processes. Although a cure for MS does not currently exist, therapies can help treat MS attacks, attenuate disease activity, reduce progress of the disease, and manage symptoms.
Translational Neuroimmunology in Multiple Sclerosis provides an overview of recent findings and knowledge of the neuroimmunology of multiple sclerosis, from experimental models and the human disease to the translation of this research to immunotherapeutic strategies. Chapters describe genetic and environmental factors underlying the disease pathogenesis of MS as a basis for development of immunotherapies, immunological markers of disease activity, pharmacogenetics, and responses to therapy. Immunomodulatory therapies currently in practice and future therapeutic strategies on the horizon—such as neuroprotective strategies, stem cells, and repair promotion—are discussed. Contributed by renowned leaders in the field, this cross-disciplinary volume is a great resource for basic scientists and clinical practitioners in neuroscience, neurology, immunology, pharmacology, and in-drug development.
- Provides an overview of recent findings and knowledge of the neuroimmunology of multiple sclerosis and the translation of this research to immunotherapy treatment
- Edited by renowned leaders in the field of neuroimmunology and multiple sclerosis
- Contains the latest resource material for basic and clinical scientists and practitioners in neuroscience, neurology, immunology, and pharmacology
- 2017 BMA Medical Book Awards Highly Commended in Neurology
Basic and clinical scientists and practitioners in neuroscience, neurology, immunology, and pharmacology
Section I: MS Pathology and Mechanisms
1. MS Pathology: Inflammation versus Neurodegeneration
2. Immune Dysregulation in Multiple Sclerosis
3. CNS immune regulation
4. Genetics of Multiple Sclerosis
5. MS Subtypes: How the Natural History of MS was Challenged Due to Treatment
6. Pediatric-Onset MS as a Window into Early Disease Targets and Mechanisms
7. Sex-related factors in multiple sclerosis
Section II: Other Patho-Mechanisms
8. Environmental Factors and their regulation of immunity in MS
9. Gut Microbiota in Multiple Sclerosis: A Bioreactor driving Brain Autoimmunity
10. Neuroendocrine Checkpoints of Innate Immune Responses in Multiple Sclerosis: Reciprocal Interactions Between Body and Brain
11. Fighting chronic neuroinflammation by boosting autoimmunity: the distinction between neurodegenerative diseases and multiple sclerosis
12. Neuroactive steroids and Neuroinflammation
Section III: Surrogate Markers in Multiple Sclerosis
13. Surrogate Markers in Multiple Sclerosis: The Role of MRI
Section IV: Currently Approved Therapies – Injectable
14. Interferon β in Multiple Sclerosis: A Review
15. Glatiramer Acetate - From Bench to Bed and Back
17. Alemtuzumab (Campath-1H)
18. Currently approved DMDs-injectable: cytotoxic immunosuppressive drugs
Section V: Currently Approved DMDs – Oral
19. Fingolimod (Gilenya)
20. Oral Dimethyl Fumarate (BG-12; Tecfidera®) for Multiple Sclerosis
21. Emerging Therapies for Multiple Sclerosis
Section VI: Symptomatic and Complementary Treatments
22. Treatment of acute relapses in Multiple sclerosis
23. Shedding light on Vitamin D and MS
24. Symptomatic and Complementary Treatments
25. Cognitive Impairment in Multiple Sclerosis
Section VII: Novel and Emerging Strategies
26. Personalized Medicine and Theranostics: Applications to Multiple Sclerosis
27. Stem cell based-therapies, remyelination and repair promotion, in the treatment of multiple sclerosis
28. Stem cells in Multiple Sclerosis
29. T cell vaccination: An insight into T cell regulation
30. Reversal of Misfortune: Therapeutic Strategies on the Horizon
- No. of pages:
- © Academic Press 2016
- 10th August 2016
- Academic Press
- Hardcover ISBN:
- eBook ISBN:
PROF. RUTH ARNON, formerly Vice-President of the Weizmann Institute of Science (1988-1997), is a renowned immunologist. Prof. Arnon joined the Institute in 1960. Prior to her appointment as Vice-President, she served as Head of the Department of Chemical Immunology, and as Dean of the Faculty of Biology. From 1985 to 1994, she was the Director of the Institute's MacArthur Center for Molecular Biology of Tropical Diseases. Prof. Arnon has made significant contributions to the fields of vaccine development, cancer research and to the study of parasitic diseases. Along with Prof. Michael Sela, she developed Copaxone® a drug for the treatment of multiple sclerosis which was approved by the U.S. Food and Drug Administration, and is presently marketed in the USA, Canada the EU, Australia and many other countries worldwide. Prof. Arnon is a member of the Israel Academy of Sciences, and serves as its President since 2010. On the world scene, she is an elected member of the European Molecular Biology Organization (EMBO), and is a member of the American Philosophical Society (APS). She has served as President of the European Federation of Immunological Societies (EFIS), and as Secretary-General of the International Union of Immunological Societies (IUIS), and as a member of the European Union Research Advisory Board (EURAB). She served also as the President of the Association of Academies of Sciences in Asia (AASA). Her awards include the Robert Koch Prize in Medical Sciences, Spain's Jiminez Diaz Memorial Prize, France's Legion of Honor, the Hadassah World Organization's Women of Distinction Award, The AESKU Prize for Life Contribution to Autoimmunity, the Tovi Comet Award, the Wolf Prize for Medicine, the Rothschild Prize for Biology and the Israel Prize for Medicine. She is an Honorary Fellow of Tel-Hai College and the Holon Institute of Technology. She received Honorary Doctorates from Ben-Gurion University of the Negev, Tel-Aviv University, The Open University of Israel and Leuphana University of Luneburg, Germany.
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
Prof. Ariel Miller holds a M.D. degree from the “Sackler” school of Medicine, Tel-Aviv, and a Ph.D. degree in Experimental Sciences (Neurobiology) from the Hebrew University of Jerusalem. He is a senior neurologist since 1989. From 1989 to 1992 he was a research fellow at the Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, as a scholar of the Fogarty International Research Fellowship (N.I.H.). From 1992 to 1993: Scientist in the Department of Cell Biology, The Weizmann Institute of Science, Rehovot, Israel. He is currently the head of The Center for Multiple Sclerosis & Brain Research at Carmel Medical Center, and co-director of the Pharmacogenetics & Personalized Medicine Center, The Rappaport Faculty of Medicine & Research Institute at the Technion-Israel Institute of Technology, Haifa, Israel.
Prof. Miller is the founder and first president of the Israel Society for Neuroimmunology (President 2000-2009), elected member of the American Neurological Association (ANA) (2005), and the recipient of the Hershel Rich Technion Innovation Award - 2006, for his contribution in the field of Pharmacogenetics and 'Personalized Medicine'.
Prof. Miller's scientific and medical work is dedicated to elucidation of the mechanisms underlying Brain diseases, with special focus on implementation of therapeutic strategies for Multiple Sclerosis as well as Pharmacogenetics towards development of 'Personalized Medicine'.
Neuroimmunology & Translational Genetics Center, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
2017 BMA Medical Book Awards Highly Commended in Neurology
2017 BMA Medical Book Awards Highly Commended in Neurology
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.